Loading...
News 2018-07-12T16:50:28+00:00

2018-07-12 Emerald Health Pharmaceuticals Forms Scleroderma Clinical Advisory Board
2018-07-03 EHP Presents Preclinical Data for its Lead Drug Candidate, EHP-101, in Both Multiple Sclerosis and Scleroderma
2018-06-29 EHP to Present Preclinical Data on EHP-101 for the Treatment of Multiple Sclerosis and Scleroderma at the 28th Annual Symposium of the International Cannabinoid Research Society
2018-05-31 EHP Appoints Dr. Alain Rolland as Executive Vice President & Chief Development Officer
2018-05-31 EHP to Present at the 8th Annual LD Micro Invitational
2018-05-02 EHP Forms Multiple Sclerosis Clinical Advisory Board
2018-04-30 EHP to Participate in Neuroscience Panel at the NeuroTech Investing and Partnering Conference
2018-04-19 EHP to Present at Cannabis Invest UK Conference
2018-04-11 EHP’s Regulation A+ Offering Qualified by SEC
2018-03-21 EHP’s Cannabinoid-Derived Drug Shows Potential for Remyelination and Disease Modification for Multiple Sclerosis
2018-03-13 EHP to Participate in Neuroscience Panel and Present at Sachs BioCapital USA Forum
2018-03-05 EHP Files for Regulation A+ Offering
2018-02-26 EHP Granted FDA Orphan Drug Designation for Huntington’s Disease
2018-02-21 EHP to Present at Sachs European Life Sciences CEO Forum and Exhibition
2018-02-15 EHP Granted European Orphan Designation for Systemic Scleroderma
2018-02-06 EHP’s Scientific Team Publishes Evidence of Neuroprotection Using Patented Cannabinoid Derivative for Parkinson’s Disease
2018-01-05 EHP to Present at the Biotech Showcase™ Annual Conference
2017-10-19 EHP Granted FDA Orphan Drug Designation for Systemic Scleroderma
2017-09-20 EHP’s Scientific Team Leads Cannabinoid Research Showing Potential to Impact Neurodegenerative Diseases
2017-09-14 EHP to Treat Life-Threatening Diseases with Novel Synthetic Cannabinoid-Derived Molecules